Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · IEX Real-Time Price · USD
1.710
-0.150 (-8.06%)
At close: May 17, 2024, 4:00 PM
1.760
+0.050 (2.92%)
After-hours: May 17, 2024, 7:51 PM EDT
Atai Life Sciences Market Cap
Atai Life Sciences has a market cap or net worth of $286.28 million as of May 17, 2024. Its market cap has decreased by -13.77% in one year.
Market Cap
286.28M
Enterprise Value
195.32M
1-Year Change
-13.77%
Ranking
Category
Stock Price
$1.71
Market Cap Chart
Since the IPO on June 18, 2021, Atai Life Sciences's market cap has decreased from $2.29B to $286.28M, a decrease of -87.49%. That is a compound annual growth rate of -51.02%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
May 16, 2024 | 311.40M | -9.27% |
May 15, 2024 | 343.20M | 8.23% |
May 14, 2024 | 317.10M | -1.55% |
May 13, 2024 | 322.10M | 2.65% |
May 10, 2024 | 313.80M | -7.81% |
May 9, 2024 | 340.40M | 2.01% |
May 8, 2024 | 333.70M | -1.97% |
May 7, 2024 | 340.40M | -3.30% |
May 6, 2024 | 352.00M | 3.41% |
May 3, 2024 | 340.40M | -3.73% |
May 2, 2024 | 353.60M | 3.88% |
May 1, 2024 | 340.40M | 3.56% |
Apr 30, 2024 | 328.70M | 0.49% |
Apr 29, 2024 | 327.10M | 2.09% |
Apr 26, 2024 | 320.40M | 4.88% |
Apr 25, 2024 | 305.50M | -1.61% |
Apr 24, 2024 | 310.50M | -5.07% |
Apr 23, 2024 | 327.10M | 5.35% |
Apr 22, 2024 | 310.50M | 1.11% |
Apr 19, 2024 | 307.10M | -3.15% |
Apr 18, 2024 | 317.10M | -3.53% |
Apr 17, 2024 | 328.70M | -7.93% |
Apr 16, 2024 | 357.00M | 3.87% |
Apr 15, 2024 | 343.70M | -10.00% |
Apr 12, 2024 | 381.90M | -6.88% |
View and export this data all the way back to 2021.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Verastem | 304.41M |
Sharecare | 302.87M |
SOPHiA GENETICS | 301.37M |
Emergent BioSolutions | 300.26M |
XOMA Corporation | 299.14M |
Xeris Biopharma Holdings | 297.25M |
TriSalus Life Sciences | 296.77M |
MacroGenics | 293.20M |